{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-018955","form_type":"8-K","ticker":"NXGL","cik":"0001468929","company_name":"NEXGEL, INC.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.553182+00:00","generated_at":"2026-06-02T02:10:13.269473+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NEXGEL Q1 revenue $1.27M (+104% YoY); net loss $905K vs $807K YoY","bullets":["Revenue increased 104% to $1.27M, driven by contract manufacturing (+58%) and branded products (+178%).","Gross profit turned positive to $277K from a loss of $57K YoY; gross margin 21.9% vs negative 9.2%.","Net loss widened to $905K from $807K; SG&A up 43.8% to $1.1M on higher advertising and consulting costs.","Cash balance $2.4M as of March 31, 2024, including ~$1M insider-led registered direct offering.","Capacity expansion in Texas nearly complete; product launches with Abbvie and European market entry expected."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-018955","json":"https://secwatch.observer/filing/0001493152-24-018955.json","markdown":"https://secwatch.observer/filing/0001493152-24-018955.md","text":"https://secwatch.observer/filing/0001493152-24-018955.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468929/000149315224018955/0001493152-24-018955-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468929/000149315224018955/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:10:13.269473+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ad176ad5710f69827be05743fd84278c73ce867a","claim":"NEXGEL, INC. reported the quarter ended March 31, 2024 results: revenue $1.27 million, net income $905,000.","evidence_excerpt":"as shall be expressly set forth by specific reference in such a filing. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 NEXGEL Reports First Quarter 2024 Revenue of $1.27 Million, an Increase of 104% Year-Over-Year LANGHORNE, Pa. – May 13, 2024 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1468929/000149315224018955/0001493152-24-018955-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$1.27 million"},{"label":"Net income","value":"$905,000"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}